Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Life Technologies and VelaDx to Develop IVD Tests

By LabMedica International staff writers
Posted on 10 Oct 2012
VelaDx (The Kendall Science Park II, Singapore) signed an agreement with Life Technologies (Carlsbad, CA, USA) to develop and market in vitro diagnostic (IVD) tests on the Ion personal genome machine (PGM) platform. More...
VelaDx will seek approvals from global regulatory authorities for clinical diagnostic tests in oncology and infectious disease.

The Ion PGM System is fast, simple, and flexible, and is complementary to Vela's Sentosa workflow and its menu of quantitative polymerase chain reaction (qPCR) assay kits. Both Ion's PGM and Vela's Sentosa systems can operate on a menu of single tests or multiple panels that can easily be implemented in most laboratories. Data communication with laboratory information systems between the Ion PGM and Sentosa systems will maintain the accuracy of data and improve the efficiency of the laboratory workflow.

The semiconductor sequencing will increase and improve diagnostic tests for personalized medicine. Ion Torrent (Guilford, CA, USA) president and COO, Gregg Fergus explained, "The Ion PGM sequencer uses a novel sequencing technology that directly translates the language of chemistry into the binary language of computers on a semiconductor chip. This new approach has democratized sequencing, making it far more accessible than ever before. The system can perform a sequencing run in just 90 minutes and automated sample prep makes it easy for a lab technician of any experience level to operate. The cost of the Ion PGM system is just a fraction of other systems and accuracy is at a Q30 quality level, both of which are helping to rapidly drive adoption. More than 1,000 units were sold in the system's first 18 months on the market. Life Technologies plans to seek clearance for the Ion PGM System from the FDA as well as approval from other global regulatory agencies."

Target markets addressed by VelaDx are attractive and growing quickly. A recent report by Piper Jaffray, an investment bank and asset management firm, estimated the current infectious disease market to be USD 2 billion annually and growing by more than 8%. United Health Group, a health care company, predicted that the genetic testing market will grow to USD 25 billion by 2021.

Related Links:
VelaDx
Life Technologies
Ion Torrent


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
All-in-One Molecular System
AIO M160
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.